#USA #FDA #Santa Cruz #Emboline #Emboliner

Emboline's Milestone in Embolic Protection Technology

On October 1, 2026, Emboline, Inc., a pioneering medical technology firm, successfully completed the first commercial use of its innovative Emboliner® Embolic Protection System in the United States. This monumental event took place at the New York-Presbyterian/Columbia University Irving Medical Center during two transcatheter aortic valve implantation (TAVR) procedures under the skilled hands of Dr. Tamim Nazif, Co-Director of the Structural Heart and Valve Center.

The Emboliner® system is designed to offer comprehensive embolic protection by effectively capturing and eliminating debris that may arise during transcatheter structural heart operations. Since its FDA 510(k) clearance in September 2026, the system has been positioned as a vital tool for enhancing patient safety during heart surgeries, particularly in TAVR procedures, where the risk of stroke and embolic debris poses significant clinical challenges.

According to Scott Russell, President and CEO of Emboline, "The completion of the first commercial Emboliner procedures in the U.S. is not just a milestone for our company; it represents a promising new option for clinicians and their patients aiming for safer procedural outcomes." He expressed gratitude toward Dr. Nazif and the entire Columbia team for their collaboration in advancing this technology to market.

The journey leading up to this significant launch is backed by extensive research and clinical trials, particularly noted in the PROTECT H2H study, where Dr. Nazif and his team acquired substantial hands-on experience with the Emboliner system. Dr. Nazif commented on the importance of the Emboliner system by stating, "Stroke and embolic debris are ongoing concerns during TAVR procedures, and we have long sought an effective solution. This system will now allow us to provide enhanced protection to our patients, addressing an unmet clinical need."

Emboline plans to initiate a phased commercial rollout, starting with top-tier structural heart centers across the country. As the company aims to establish their product within the competitive market of embolic protection systems, it remains focused on delivering groundbreaking solutions that will further shape the landscape of cardiovascular procedures.

About Emboline

Founded and headquartered in Santa Cruz, California, Emboline, Inc. is a privately held medical technology enterprise dedicated to the development of innovative devices that significantly reduce the risk of embolic complications during cardiovascular procedures. The Emboliner® Embolic Protection System highlights the company’s commitment to improving procedural safety and patient outcomes in the rapidly evolving field of cardiac intervention. This novel technology is the brainchild of Dr. Amir Belson, a serial medical device entrepreneur who has a track record of successful innovations in healthcare. For more information about Emboline and its products, please visit emboline.com.